Survey: stage II use and clinician equipoise

Dr Stacey A Cohen from the University of Washington in Seattle, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora discuss the role of molecular residual disease assessment using circulating tumor DNA-based tools in the management of colorectal cancer.

CME information and select publications here.